The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
Harbour BioMed brings advanced antibody discovery platforms to the table
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The move strengthens GBL’s clinical-stage presence in the United States
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The new centre brings advanced corneal procedures pioneered in India
Subscribe To Our Newsletter & Stay Updated
